Core Alternative Capital Cuts Stock Position in Eli Lilly and Company $LLY

Core Alternative Capital trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 10.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,920 shares of the company’s stock after selling 1,318 shares during the period. Eli Lilly and Company comprises 2.6% of Core Alternative Capital’s holdings, making the stock its 5th largest position. Core Alternative Capital’s holdings in Eli Lilly and Company were worth $9,095,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the period. OneAscent Wealth Management LLC grew its position in shares of Eli Lilly and Company by 32.0% in the 2nd quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock valued at $280,000 after acquiring an additional 87 shares during the period. Patton Fund Management Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth about $211,000. Finally, Venture Visionary Partners LLC raised its holdings in shares of Eli Lilly and Company by 16.6% in the 2nd quarter. Venture Visionary Partners LLC now owns 12,046 shares of the company’s stock valued at $9,390,000 after purchasing an additional 1,712 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Berenberg Bank increased their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Finally, The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $1,173.91.

Eli Lilly and Company Stock Performance

LLY opened at $1,038.23 on Wednesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business has a fifty day simple moving average of $1,058.15 and a 200 day simple moving average of $885.09. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a market capitalization of $981.52 billion, a PE ratio of 50.79, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue was up 53.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong commercial momentum from Lilly’s weight‑loss and diabetes franchise continues to underpin investor bullishness, supporting high revenue and EPS guidance. Up 36%, Is Eli Lilly Still a Buy?
• Positive Sentiment: Clinical and R&D advances — including completion of the pirtobrutinib Phase 1/2 study segment — add upside optionality in oncology/BTK space if later‑stage data hold up. Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race
• Positive Sentiment: Pipeline and strategic tech investment headlines (FDA Breakthrough designation for a candidate plus an AI partnership) support long‑term growth expectations beyond GLP‑1s. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Neutral Sentiment: Analyst pieces and stock‑watch coverage note Lilly’s heavy market interest and valuation questions — useful for framing risk/reward but not immediate catalysts. Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Marketing shifts (focus on “weight stigma”) reflect competitive positioning as GLP‑1 competition heats up; relevant for long‑term brand/market share but not an immediate earnings shock. Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’
• Negative Sentiment: The U.S. CMS added multiple Lilly branded drugs to the next cycle of the Medicare Drug Price Negotiation Program, increasing potential downward pressure on future pricing and margins for affected products (including the first Part B reimbursements). US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: The American Hospital Association and other hospital groups are urging regulators to block Lilly’s new 340B claims‑data submission policy, creating regulatory/legal uncertainty and potential commercial/frictional headwinds with hospitals. AHA Urges HRSA to Stop Eli Lilly’s New Policy on 340B Hospitals From Going into Effect

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.